{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not estimable due to low number of events","groupId":"OG000","lowerLimit":"35.7","upperLimit":"NA","value":"49.8"},{"comment":"Upper limit was not estimable due to low number of events","groupId":"OG001","lowerLimit":"38.5","upperLimit":"NA","value":"51.5"},{"comment":"Upper limit was not estimable due to low number of events","groupId":"OG002","lowerLimit":"41.1","upperLimit":"NA","value":"53.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"167"}],"units":"Participants"}],"description":"Overall survival is defined as the time between randomization and death. Participants still alive at the cutoff date or lost to follow-up were censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bortezomib (Velcade) 1.3 mg/m\\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG000","title":"Bortezomib and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG001","title":"Bortezomib, Thalidomide, and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG002","title":"Bortezomib, Melphalan and Prednisone"}],"paramType":"MEDIAN","populationDescription":"Intent to treat","reportingStatus":"POSTED","timeFrame":"From randomization until death. Median follow-up time was 43 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}